New drug cocktail targets tough lung cancer
NCT ID NCT07283198
First seen Jan 11, 2026 · Last updated Jun 20, 2026 · Updated 23 times
Summary
This study tests a new drug called JSKN033 in 160 people with advanced non-small cell lung cancer that cannot be cured. JSKN033 combines two drugs: one targets HER2 on cancer cells, and the other helps the immune system attack the tumor. The goal is to see if the drug shrinks tumors and to check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JSKN033 (a combination of a HER2-targeted antibody-drug conjugate and a PD-L1 inhibitor)
What this could lead to
If successful, this could provide a new treatment option for people with advanced non-small cell lung cancer who have limited choices.
What could go wrong
This is an early Phase 2 study with a small number of participants, so results may not apply to all patients. Side effects from the drug combination could be significant.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.